4.7 Review

Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications

Journal

PHARMACEUTICS
Volume 14, Issue 10, Pages -

Publisher

MDPI
DOI: 10.3390/pharmaceutics14102220

Keywords

Hsp90 inhibitor; co-chaperone; heterocycle molecules; anticancer agents; heat shock proteins

Funding

  1. National Institute for Medical Research Development [988767]
  2. Pharmaceutical Sciences Research Center [298121, 140192]

Ask authors/readers for more resources

Heat shock proteins (Hsps) play important roles in cancer therapy, and Hsp90 inhibitors are attractive therapeutic agents that can inhibit tumor growth and development.
Heat shock proteins (Hsps) have garnered special attention in cancer therapy as molecular chaperones with regulatory/mediatory effects on folding, maintenance/stability, maturation, and conformation of proteins as well as their effects on prevention of protein aggregation. Hsp90 ensures the stability of various client proteins needed for the growth of cells or the survival of tumor cells; therefore, they are overexpressed in tumor cells and play key roles in carcinogenesis. Accordingly, Hsp90 inhibitors are recognized as attractive therapeutic agents for investigations pertaining to tumor suppression. Natural Hsp90 inhibitors comprising geldanamycin (GM), reclaimed analogs of GM including 17-AAG and DMAG, and radicicol, a natural macrocyclic antifungal, are among the first potent Hsp90 inhibitors. Herein, recently synthesized heterocyclic compounds recognized as potent Hsp90 inhibitors are reviewed along with the anticancer effects of heterocyclic compounds, comprising purine, pyrazole, triazine, quinolines, coumarin, and isoxazoles molecules.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available